Finance Watch: Cytokinetics Accesses Up To $1bn-Plus, Confirms No-Sale Plan
Company’s Stock Plunged In Absence Of M&A Deal
Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.
